Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2005
Brief Summary: 800 RRMS Subjects currently treated with Avonex or Copaxone will be randomized to either continue on their current therapy or receive Rebif therapy. The subjects will be followed for 2 years. The primary objective is to compare the time to worsening to a medium level of concern as defined by the Canadian Multiple Sclerosis Working Group (CMSWG) treatment optimization recommendations.
Epistemonikos ID: 91ff771c57856fd5bf1a980fe3233fa3ad53b0cd
First added on: Mar 31, 2022